| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Over the last 12 months, insiders at Lineage Cell Therapeutics, Inc. have bought $0 and sold $0 worth of Lineage Cell Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Lineage Cell Therapeutics, Inc. have bought $4.43M and sold $2.7M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,894,737 shares for transaction amount of $6M was made by BROADWOOD PARTNERS, L.P. () on 2025‑01‑27.
| 2025-01-27 | BROADWOOD PARTNERS, L.P. | 7.89M 4.4378% | $0.76 | $6M | +65.85% | |||
| 2024-11-26 | Howe Jill Ann | Chief Financial Officer | 15,000 0.0082% | $0.59 | $8,850 | +14.87% | ||
| 2024-11-26 | Samuel George A. III | General Counsel | 15,000 0.0083% | $0.60 | $9,000 | +14.87% | ||
| 2024-11-22 | Mulroy Michael H. | director | 40,000 0.0237% | $0.57 | $22,640 | +36.83% | ||
| 2024-11-21 | Culley Brian M | President and CEO | 40,000 0.0213% | $0.60 | $24,000 | +14.63% | ||
| 2024-08-16 | Howe Jill Ann | Chief Financial Officer | 10,500 0.0059% | $0.89 | $9,345 | -20.63% | ||
| 2024-05-24 | Culley Brian M | President and CEO | 10,000 0.0054% | $1.05 | $10,500 | -31.53% | ||
| 2024-02-08 | BAILEY DON M | director | 96,155 0.0563% | $1.04 | $100,001 | -15.51% | ||
| 2024-02-06 | BROADWOOD PARTNERS, L.P. | 6.73M 3.9412% | $1.04 | $7M | -17.65% | |||
| 2023-12-29 | Jayasuriya Anula | director | 10,000 0.0057% | $1.09 | $10,900 | -11.37% | ||
| 2022-03-31 | Culley Brian M | President and CEO | 6,400 0.0037% | $1.53 | $9,792 | -11.04% | ||
| 2022-03-28 | Amin Dipti | 35,000 0.0227% | $1.63 | $57,050 | -7.43% | |||
| 2022-03-25 | Culley Brian M | President and CEO | 5,250 0.0029% | $1.38 | $7,245 | -7.43% | ||
| 2022-03-24 | Mulroy Michael H. | 7,000 0.004% | $1.40 | $9,800 | -4.86% | |||
| 2022-03-23 | BRADSHER NEAL C | 0 – | $0 | $0 | -0.72% | |||
| 2021-12-29 | Sale | Hogge Gary S. | SVP,Clinical & Medical Affairs | 37,695 0.0227% | $2.45 | $92,438 | -43.21% | |
| 2021-12-28 | Sale | Hogge Gary S. | SVP,Clinical & Medical Affairs | 501,588 0.298% | $2.45 | $1.23M | -43.70% | |
| 2021-06-29 | Sale | Russell Angus C. | director | 4,720 0.0029% | $2.97 | $14,018 | -29.69% | |
| 2021-06-29 | Sale | ANDREWS DEBORAH J | director | 19,142 0.0117% | $2.93 | $56,086 | -29.69% | |
| 2021-06-28 | Sale | Culley Brian M | President and CEO | 450,000 0.2743% | $2.87 | $1.29M | -28.72% |
| BROADWOOD PARTNERS, L.P. | 49560992 21.5176% | $83.76M | 20 | 1 | +9.11% | |
| BRADSHER NEAL C | 34265485 14.8769% | $57.91M | 4 | 0 | <0.0001% | |
| KINGSLEY ALFRED D | See Remarks | 5781555 2.5101% | $9.77M | 13 | 8 | |
| WEST MICHAEL D | Co-Chief Executive Officer | 882864 0.3833% | $1.49M | 3 | 1 | +1.12% |
| SEGALL JUDITH | Vice President & Secretary | 520415 0.2259% | $879,501.35 | 0 | 4 | |
| Peabody Robert | Sr. VP, COO, and CFO | 315777 0.1371% | $533,663.13 | 1 | 1 | +6.44% |
| Mulroy Michael H. | director | 298555 0.1296% | $504,557.95 | 2 | 0 | +15.99% |
| STERNBERG HAL | Vice President | 254270 0.1104% | $429,716.30 | 0 | 1 | |
| Culley Brian M | President and CEO | 194842 0.0846% | $329,282.98 | 5 | 1 | <0.0001% |
| WAITZ HAROLD D | Vice President | 184246 0.08% | $311,375.74 | 0 | 2 | |
| BAILEY DON M | director | 158801 0.0689% | $268,373.69 | 1 | 0 | <0.0001% |
| Cartt Stephen LaHue | director | 155125 0.0673% | $262,161.25 | 3 | 0 | +6.94% |
| LICHTINGER PEDRO | director | 126250 0.0548% | $213,362.50 | 2 | 0 | <0.0001% |
| FARRELL STEPHEN C | director | 97450 0.0423% | $164,690.50 | 6 | 0 | <0.0001% |
| MOHANTY ADITYA P. | Co-Chief Executive Officer | 89696 0.0389% | $151,586.24 | 1 | 0 | <0.0001% |
| Russell Angus C. | director | 87500 0.038% | $147,875.00 | 1 | 1 | <0.0001% |
| Amin Dipti | 35000 0.0152% | $59,150.00 | 1 | 0 | <0.0001% | |
| SCHLACHET DAVID | director | 32050 0.0139% | $54,164.50 | 1 | 0 | +11.75% |
| Howe Jill Ann | Chief Financial Officer | 25500 0.0111% | $43,095.00 | 2 | 0 | <0.0001% |
| SEINBERG STEVEN A | Chief Financial Officer | 22500 0.0098% | $38,025.00 | 0 | 4 | |
| Samuel George A. III | General Counsel | 22184 0.0096% | $37,490.96 | 1 | 0 | +14.87% |
| ANDREWS DEBORAH J | director | 15578 0.0068% | $26,326.82 | 5 | 1 | <0.0001% |
| BURNS ARNOLD I | director | 15000 0.0065% | $25,350.00 | 1 | 0 | <0.0001% |
| COHEN ABRAHAM E | director | 10000 0.0043% | $16,900.00 | 1 | 0 | <0.0001% |
| Jayasuriya Anula | director | 10000 0.0043% | $16,900.00 | 1 | 0 | <0.0001% |
| Patton Stephana Eilene | General Counsel | 7500 0.0033% | $12,675.00 | 1 | 0 | <0.0001% |
| GARCIA PETER S | Chief Financial Officer | 7000 0.003% | $11,830.00 | 2 | 0 | <0.0001% |
| Roberts Brandi | CFO & SVP, Finance | 5000 0.0022% | $8,450.00 | 1 | 0 | <0.0001% |
| Leavitt Chase C. | General Counsel/Secretary | 5000 0.0022% | $8,450.00 | 1 | 0 | <0.0001% |
| TEW WILLIAM P PHD | Chief Commercial Officer | 3265 0.0014% | $5,517.85 | 0 | 5 | |
| VON ESCHENBACH ANDREW C. | director | 3000 0.0013% | $5,070.00 | 1 | 0 | <0.0001% |
| SKIBSTED RUSSELL | Chief Financial Officer | 2000 0.0009% | $3,380.00 | 1 | 0 | <0.0001% |
| BERGER FRANKLIN M | director | 500 0.0002% | $845.00 | 1 | 0 | <0.0001% |
| GREGG VALETA A | director | 0 0% | $0 | 0 | 8 | |
| Hogge Gary S. | SVP,Clinical & Medical Affairs | 0 0% | $0 | 0 | 2 | |
| Hernandez Alexandra | Sr Director Finance/Controller | 0 0% | $0 | 0 | 1 |
$5,960,789 | 91 | -7.17% | $354.54M | |
$5,911,307 | 70 | -1.38% | $354.76M | |
Lineage Cell Therapeutics, Inc. (LCTX) | $54,836,085 | 68 | -0.52% | $389.25M |
$17,468,215 | 46 | 18.85% | $453.07M | |
$130,095 | 43 | 45.19% | $374.39M | |
$24,384,691 | 42 | -30.27% | $397.16M | |
$74,231,875 | 30 | 40.62% | $421.18M | |
$104,137,421 | 15 | 21.28% | $358.22M | |
$81,667,942 | 12 | -57.54% | $399.99M | |
$112,952,085 | 11 | -19.19% | $362.38M | |
$603,645 | 8 | 57.40% | $373.05M | |
$14,995,689 | 8 | 3.76% | $366.47M | |
$166,385 | 7 | -23.62% | $457.44M | |
$79,246,559 | 5 | -27.73% | $428.51M | |
$12,035,408 | 5 | -37.54% | $362.3M | |
$4,745,999 | 5 | -4.91% | $397.29M | |
$10,104,842 | 3 | 5.45% | $458.36M | |
$136,410 | 2 | -13.40% | $359.38M | |
$3,850,000 | 1 | -51.32% | $407.01M |
| Increased Positions | 51 | +35.92% | 10M | +10.39% |
| Decreased Positions | 51 | -35.92% | 3M | -3.23% |
| New Positions | 19 | New | 3M | New |
| Sold Out Positions | 22 | Sold Out | 979,952 | Sold Out |
| Total Postitions | 142 | 0% | 103M | +7.16% |
| Broadwood Capital Inc | $81,280.00 | 21.55% | 49.56M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $14,771.00 | 3.92% | 9.01M | +524,057 | +6.18% | 2025-09-30 |
| Defender Capital, Llc. | $11,163.00 | 2.96% | 6.81M | +21,400 | +0.32% | 2025-09-30 |
| Raffles Associates Lp | $8,836.00 | 2.34% | 5.39M | -4,300 | -0.08% | 2025-09-30 |
| Comerica Bank | $7,544.00 | 2% | 4.6M | 0 | 0% | 2025-09-30 |
| Millennium Management Llc | $4,395.00 | 1.17% | 2.68M | +79,426 | +3.05% | 2025-09-30 |
| Geode Capital Management, Llc | $3,968.00 | 1.05% | 2.42M | -11,853 | -0.49% | 2025-09-30 |
| Blackrock, Inc. | $3,658.00 | 0.97% | 2.23M | -29,992 | -1.33% | 2025-09-30 |
| Renaissance Technologies Llc | $3,125.00 | 0.83% | 1.91M | -66,702 | -3.38% | 2025-09-30 |
| Dauntless Investment Group, Llc | $2,647.00 | 0.7% | 1.61M | +408,170 | +33.85% | 2025-09-30 |